Combination therapy resulted in significantly fewer BCR-ABL transcripts in transgenic CML mice than controls (P < 0.01). The combination also yielded a survival benefit over dasatinib monotherapy (P = 0.018) and vehicle (P = 0.001). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.